Ibn Sina Pharma’s profit doubles in Jul-Sept

The Ibn Sina Pharmaceutical Industry reported a sharp rise in earnings in the July-September quarter, with profit more than doubling on the back of strong revenue growth and higher other income.

Its net profit jumped 160 percent year-on-year to Tk 22 crore, according to the company's financial statements.

The company's revenue climbed 35 percent year-on-year to Tk 372 crore, while other income rose 13 percent to Tk 94 lakh.

Its earnings per share surged to Tk 7.08 in the July-September period, compared with Tk 2.72 in the same period a year earlier.

The company's net operating cash flow per share, however, fell to Tk 5.46 from Tk 9.71.

The company's revenue climbed 35 percent year-on-year to Tk 372 crore

The Dhaka Stock Exchange data show that as of October 31, 2025, sponsors and directors held 44.68 percent of shares of Ibn Sina Pharma, the public 31.89 percent, with the remainder owned by institutional and foreign investors.

Ibn Sina Pharmaceutical Industry, founded in 1983, began commercial production in 1986 and became publicly listed in 1989.

It introduced ophthalmic products (medicines and solutions specifically for eye care) in 1995, natural medicine (herbal or plant-based remedies) in 2008, and a cephalosporin (antibiotics used to treat bacterial infections) plant in 2016.

It now markets over 100 products across Bangladesh's healthcare sector, according to its website.